Clinical Trials · NCT05856630
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
- Phase
- Phase 1
- Recruitment status
- Unknown
- Sponsor
- Luye Pharma Group Ltd.
- Enrollment
- 24
- Start date
- May 2023
- Locations
- 1 site, China
- Primary endpoint
- Changes in plasma goserelin concentration after administration of LY01022 or Zoladex®